IP Library Granted Patent US 11,931,411
Granted Patent B2
US 11,931,411 · App. 17/523,648 · Granted Mar 19, 2024

Allergen desensitization method

Inventors: Christophe Dupont (Clamart, FR); Pierre-Henri Benhamou (Paris, FR); Bertrand Dupont (Aix en Provence, FR)
Assignees: DBV Technologies; Assistance Pulique-Hoôpitaux De Paris; Université de Paris Cité
A61K39/35A61K9/0014A61K9/7007A61K39/36A61K9/7023A61K2039/54A61K2039/545
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,931,411
App. No.
17/523,648
Granted
Mar 19, 2024
Kind
B2
Abstract

The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.

Claims (24)

1. A method for epicutaneous desensitization of a subject allergic to an allergen, the method comprising:

a) epicutaneously exposing the subject to the allergen and generating an immune reaction in the subject by applying a dose of the allergen, without an adjuvant, onto an intact region of skin of the subject; and

b) repeatedly applying the allergen, without an adjuvant, to an intact region of the skin of the subject, at a dose, frequency or for an application time adapted to sustain the immune reaction, the exposure and sustained reaction leading to desensitization of the subject;

wherein the allergen is applied by a cutaneous occlusive device configured to ensure contact between the allergen and the region of skin, and wherein said dose of allergen is comprised between 0.1 and 1,000 μg/cm 2 of a surface area of the device.

2. The method of claim 1 , further comprising visually evaluating the immune reaction.

3. The method of claim 1 , wherein the allergen is in powder form.

4. The method of claim 1 , wherein the immune reaction generated during the generating step is visible to the naked eye.

5. The method of claim 4 , wherein the immune reaction comprises an infiltrated erythematous lesion.

6. The method of claim 4 , wherein the immune reaction has an eczematiform aspect.

7. The method of claim 1 , wherein the device comprises a transparent backing configured to allow the immune reaction to be viewed.

8. The method of claim 7 , wherein the backing comprises a grid configured to aid in an evaluation of the immune reaction.

9. The method of claim 1 , wherein the device is removable.

10. The method of claim 1 , further comprising determining the immune reaction of the subject generated by different doses of the allergen.

11. The method of claim 1 , further comprising

determining the immune reaction of the subject generated by different forms of the allergen; and

selecting a form of allergen for the treatment based on said determination.

12. The method of claim 1 , wherein the allergen is selected from a food allergen and a respiratory allergen.

13. The method of claim 12 , wherein the food allergen is selected from the group consisting of groundnut, shellfish, egg, fish, wheat, and soya bean.

14. The method of claim 12 , wherein the respiratory allergen is selected from the group consisting of mites, pollen, and animal hair.

15. The method of claim 1 , wherein the allergen is in the form of a protein extract.

16. The method of claim 1 , wherein during the repeated applications in step (b), the immune reaction decreases.

17. The method of claim 1 , wherein during the repeated applications in step (b), the immune reaction increases.

18. The method of claim 9 , comprising increasing the dose, frequency, or application time of the allergen during the repeated applications in step (b) as the immune reaction decreases during the repeated applications in step (b).

19. The method of claim 9 , comprising decreasing the dose, frequency, or application time of the allergen during the repeated applications in step (b) as the immune reaction increases during the repeated applications in step (b).

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2023
From: DUPONT, CHRISTOPHE; BENHAMOU, PIERRE-HENRI; DUPONT, BERTRAND
To: DBV TECHNOLOGIES
Reel/Frame 062502/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2023
From: DBV TECHNOLOGIES
To: DBV TECHNOLOGIES; L'ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; UNIVERSITE PARIS DESCARTES
Reel/Frame 062521/0170 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBER 16930208 PREVIOUSLY RECORDED AT REEL: 060541 FRAME: 0336. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME. Recorded Jan 11, 2023
From: UNIVERSITE PARIS DESCARTES; UNIVERSITE PARIS DIDEROT - PARIS 7
To: UNIVERSITE DE PARIS
Reel/Frame 062387/0346 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBER 16930208 PREVIOUSLY RECORDED AT REEL: 060390 FRAME: 0122. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jan 11, 2023
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 062387/0489 →
CHANGE OF NAME Recorded Jun 20, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 060390/0122 →
MERGER AND CHANGE OF NAME Recorded Jun 20, 2022
From: UNIVERSITE PARIS DESCARTES; UNIVERSITE PARIS DIDEROT - PARIS 7; UNIVERSITE DE PARIS
To: UNIVERSITE DE PARIS
Reel/Frame 060541/0336 →